Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Innovent Biologics, Inc. (1801.HK)
Suzhou, CN
Innovent Biologics, Inc., established in 2011 and headquartered in Suzhou, People's Republic of China, functions as a leading biopharmaceutical enterprise. The company is dedicated to the comprehensive lifecycle of antibody drug candidates, encompassing their discovery, development, and eventual manufacturing. Its therapeutic focus spans critical areas such as oncology, ophthalmology, immunology, and metabolic diseases. A key product in its portfolio is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody utilized in the treatment of various cancers, including Hodgkin's lymphoma and esophageal carcinoma. Innovent's commercialized offerings also include Byvasda, employed for several malignant tumors; Halpryza, which addresses non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and Wegener's granulomatosis; Pemazyre, indicated for adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib, designed for adult patients facing conditions related to tyrosine kinase inhibitors; and Cyramza, approved for four distinct cancer types. The company's robust pipeline features a range of investigational therapies, such as IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein aimed at ocular fundus disease; IBI-306, a human monoclonal antibody targeting hypercholesterolemia; and IBI-310, a recombinant human anti-CTLA-4 monoclonal antibody for liver and renal cell carcinoma. Further developmental assets include IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for adults with relapsed or refractory multiple myeloma; IBI-376 for recurrent or refractory follicular lymphoma; and IBI-112 for psoriasis. Beyond drug creation, Innovent Biologics is also involved in distributing pharmaceutical products and provides expert consultation along with research and development services. The company maintains key strategic alliances with various partners, including NeoCura Bio-Medical Technology Co. Ltd., Roche Group, Ascentage Pharma Group International, Eli Lilly and Company, and Bolt Biotherapeutics, Inc.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +11.36% | +3.80% | -7.39% | -2.06% | -11.42% | +9.31% | +34.54% | +127.42% | -11.28% | +402.71% | +402.71% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 5 | 0 |
| Buy | 22 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+38.4% ★ Q4'25: +102.3% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+933.3% ★ Q4'25: +97.9% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+65.8% Q4'25: +133.1% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+5.6% ★ Q4'25: -0.1% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+18.1% ★ Q4'25: -0.5% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+7.0% Q4'25: +12.9% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×2.15× ★ Q4'25: 1.69× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 30 Rev. Ana. 20 EPS Ana. |
Dec 2027 29 Rev. Ana. 19 EPS Ana. |
Dec 2028 22 Rev. Ana. 17 EPS Ana. |
Dec 2029 15 Rev. Ana. 13 EPS Ana. |
Dec 2030 11 Rev. Ana. 7 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
9.48M
est: 12.07M (-21.5%)
|
1.05B
est: 973.95M (+7.6%)
|
3.84B
est: 3.82B (+0.5%)
|
4.27B
est: 5.00B (-14.6%)
|
4.56B
est: 5.26B (-13.4%)
|
6.21B
est: 6.94B (-10.5%)
|
9.42B
est: 8.27B (+14.0%)
|
13.04B
est: 12.99B (+0.4%)
|
19.13B
15.61B – 28.46B
+47.3% YoY
|
22.92B
18.64B – 27.25B
+19.8% YoY
|
27.09B
22.06B – 35.89B
+18.2% YoY
|
34.26B
27.91B – 45.39B
+26.5% YoY
|
39.07B
31.82B – 51.76B
+14.0% YoY
|
| EBITDA |
-5.74B
est: -3.09M (-185,545.9%)
|
-1.57B
est: -249.49M (-530.9%)
|
-704.74M
est: -979.66M (+28.1%)
|
-2.37B
est: -1.28B (-85.4%)
|
-1.75B
est: -1.35B (-29.8%)
|
-660.68M
est: -1.38B (+52.2%)
|
-480.28M
est: -1.65B (+70.9%)
|
1.31B
est: -2.59B (+150.6%)
|
-3.81B
-5.68B – -3.11B
-47.3% YoY
|
-4.57B
-5.43B – -3.72B
-19.8% YoY
|
-5.40B
-7.16B – -4.40B
-18.2% YoY
|
-6.83B
-9.05B – -5.56B
-26.5% YoY
|
-7.79B
-10.32B – -6.35B
-14.0% YoY
|
| EBIT |
-5.80B
est: -3.65M (-158,868.5%)
|
-1.66B
est: -294.62M (-463.6%)
|
-790.36M
est: -1.16B (+31.7%)
|
-2.58B
est: -1.51B (-70.6%)
|
-2.07B
est: -1.59B (-30.0%)
|
-1.05B
est: -1.73B (+39.7%)
|
-755.87M
est: -2.07B (+63.4%)
|
733.62M
est: -3.25B (+122.6%)
|
-4.78B
-7.12B – -3.91B
-47.3% YoY
|
-5.73B
-6.82B – -4.66B
-19.8% YoY
|
-6.78B
-8.98B – -5.52B
-18.2% YoY
|
-8.57B
-11.35B – -6.98B
-26.5% YoY
|
-9.77B
-12.95B – -7.96B
-14.0% YoY
|
| Net Income |
-5.77B
est: -1.76B (-228.2%)
|
-1.72B
est: -1.87B (+8.1%)
|
-998.42M
est: -749.87M (-33.1%)
|
-2.73B
est: -2.09B (-30.3%)
|
-2.18B
est: -3.52B (+38.1%)
|
-1.03B
est: -1.19B (+13.8%)
|
-94.63M
est: -856.16M (+88.9%)
|
813.57M
est: 730.74M (+11.3%)
|
2.40B
688.48M – 5.80B
+228.7% YoY
|
3.19B
1.23B – 7.20B
+32.9% YoY
|
4.31B
2.75B – 8.42B
+35.1% YoY
|
7.85B
5.96B – 11.16B
+81.9% YoY
|
9.78B
7.42B – 13.91B
+24.6% YoY
|
| SGA |
413.51M
est: 7.77M (+5,218.7%)
|
1.45B
est: 627.36M (+130.7%)
|
1.78B
est: 2.46B (-27.8%)
|
3.61B
est: 3.22B (+12.2%)
|
3.43B
est: 3.39B (+1.1%)
|
3.85B
est: 4.53B (-15.0%)
|
5.08B
est: 5.40B (-5.9%)
|
6.64B
est: 8.49B (-21.8%)
|
12.50B
10.20B – 18.60B
+47.3% YoY
|
14.98B
12.18B – 17.81B
+19.8% YoY
|
17.70B
14.42B – 23.45B
+18.2% YoY
|
22.39B
18.24B – 29.66B
+26.5% YoY
|
25.53B
20.80B – 33.82B
+14.0% YoY
|
| EPS |
-17.24
est: -1.08 (-1,495.6%)
|
-1.51
est: -1.15 (-31.3%)
|
-0.74
est: -0.46 (-60.6%)
|
-1.88
est: -1.29 (-46.1%)
|
-1.46
est: -1.73 (+15.8%)
|
-0.66
est: -0.74 (+11.2%)
|
-0.06
est: -0.45 (+87.1%)
|
0.48
est: 0.63 (-23.8%)
|
1.43
0.40 – 3.33
+126.5% YoY
|
2.29
0.71 – 4.13
+60.5% YoY
|
3.11
1.58 – 4.84
+36.0% YoY
|
4.51
3.42 – 6.41
+44.9% YoY
|
5.62
4.26 – 7.99
+24.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-15 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-14 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| De-Chao Yu | Co-Founder, Chairman & Chief Executive Officer | 49M | — |
| Hao Xi Ede | Executive Director & Fund Managing Partner | 8M | male |
| Qian Zhang | Chief Commercial Officer, General Manager & Executive Director | 5M | female |
| Hui Zhou | Chief R&D Officer for Oncology | — | — |
| Kaisong Zhou | Chief Operating Officer | — | — |
| Min Liu | Chief Commercial Officer | — | male |
| Raj Dhodda | Senior Vice President | — | — |
| Samuel Suhua Zhang | Global Chief Business Officer | — | — |
| Blake Salisbury | Senior Vice President | — | male |
| Zhengwei Song | Director of IR & Financial Strategy | — | female |
| Cong Ding | General Counsel | — | female |
| Fei You | Chief Financial Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1801.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
